<code id='C247A7F900'></code><style id='C247A7F900'></style>
      • <acronym id='C247A7F900'></acronym>
      <center id='C247A7F900'><center id='C247A7F900'><tfoot id='C247A7F900'></tfoot></center><abbr id='C247A7F900'><dir id='C247A7F900'><tfoot id='C247A7F900'></tfoot><noframes id='C247A7F900'>
      • <optgroup id='C247A7F900'><strike id='C247A7F900'><sup id='C247A7F900'></sup></strike><code id='C247A7F900'></code></optgroup>
        5. <b id='C247A7F900'><label id='C247A7F900'><select id='C247A7F900'><dt id='C247A7F900'><span id='C247A7F900'></span></dt></select></label></b><u id='C247A7F900'></u>
          <i id='C247A7F900'><strike id='C247A7F900'><tt id='C247A7F900'><pre id='C247A7F900'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / knowledge / hotspot      
           
     
           
      
          hotspot 
           
      
           
      
           
       2025-09-28 16:15:32 
   
      
           
      
           
                        
          hotspot  
          
                                   
                 
                                      author：hotspot   
                                        
                                      
                                      Page View：722
                                  
                                    
          
                                   
          Adam's take main illustration
          Molly Ferguson/STAT
          Biotech is awash in PIPEs.
          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.
          advertisement
          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Cytokinetics CEO stresses company can launch heart drug on its own
                                
                            
          Next article：  
                                      
                                          Hepatitis C has a cure — but many Americans still lack access to it
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles